| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | F G Hayden | |
| M Zambon | |||
| Global Neuraminidase Inhibitor Susceptibility Network | |||
| P2860 | cites work | 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro | Q28378588 |
| Influenza virus neuraminidase inhibitors | Q30305461 | ||
| Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir | Q30306773 | ||
| Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine | Q30448585 | ||
| Emergence and apparent transmission of rimantadine-resistant influenza A virus in families | Q30460018 | ||
| Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus | Q30472691 | ||
| Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors | Q33827578 | ||
| Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies | Q33978456 | ||
| Resistance of influenza viruses to neuraminidase inhibitors--a review. | Q33993985 | ||
| Influenza virus neuraminidase: structure, antibodies, and inhibitors | Q34318113 | ||
| Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection | Q36866575 | ||
| Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). | Q37513512 | ||
| Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group | Q40625504 | ||
| In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir | Q40911739 | ||
| Low incidence of rimantadine resistance in field isolates of influenza A viruses | Q40930290 | ||
| The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en | Q41027402 | ||
| Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor | Q41042625 | ||
| Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir | Q45742771 | ||
| Prolonged Shedding of Amantadine-Resistant Influenza A Viruses by Immunodeficient Patients: Detection by Polymerase Chain Reaction-Restriction Analysis | Q54159205 | ||
| Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults | Q73670502 | ||
| Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults | Q74687262 | ||
| Influenza virus resistance to neuraminidase inhibitors | Q79340361 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 147-156 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Antiviral Research | Q4775352 |
| P1476 | title | Position statement: global neuraminidase inhibitor susceptibility network | |
| P478 | volume | 49 |
| Q41745036 | A Critical Role for Immune System Response in Mediating Anti-influenza Drug Synergies Assessed by Mechanistic Modeling |
| Q30393843 | A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection |
| Q58066873 | Anti-influenza therapy: the emerging challenge of resistance |
| Q30390818 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays |
| Q44596523 | Avian flu special: what's in the medicine cabinet? |
| Q30386119 | Avian influenza--a review for doctors in travel medicine. |
| Q30394067 | Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses |
| Q34046111 | Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model |
| Q45810645 | Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States |
| Q44903223 | Current research on respiratory viral infections: Fifth International Symposium. |
| Q30309620 | Current research on respiratory viral infections: Fourth International Symposium |
| Q30379542 | Deep Sequencing for Evaluation of Genetic Stability of Influenza A/California/07/2009 (H1N1) Vaccine Viruses |
| Q30308218 | Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay |
| Q30445738 | Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. |
| Q30234600 | Drug resistance in influenza A virus: the epidemiology and management |
| Q35076785 | Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus |
| Q30448118 | Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor |
| Q30381938 | Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. |
| Q30453005 | Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. |
| Q34706374 | Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors |
| Q56969102 | Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017 |
| Q28472513 | Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses |
| Q43177625 | Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs |
| Q35024169 | Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses |
| Q44705790 | In vitro and in vivo activities of T-705 and oseltamivir against influenza virus |
| Q30364892 | Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs. |
| Q37542274 | Influenza genome analysis using pyrosequencing method: current applications for a moving target |
| Q44025966 | Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo |
| Q28471835 | Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein |
| Q36090658 | Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance |
| Q30230076 | Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planning |
| Q28263525 | Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors |
| Q28477952 | Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic |
| Q30400058 | Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus |
| Q34077100 | Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility |
| Q27021579 | Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance |
| Q24203875 | Neuraminidase inhibitors for preventing and treating influenza in children |
| Q24243136 | Neuraminidase inhibitors for preventing and treating influenza in children |
| Q24247957 | Neuraminidase inhibitors for preventing and treating influenza in children |
| Q24200222 | Neuraminidase inhibitors for preventing and treating influenza in children (published trials only) |
| Q34519220 | Neuraminidase inhibitors for the treatment and prevention of influenza |
| Q35045959 | Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy |
| Q37596932 | Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium |
| Q30452889 | Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. |
| Q37017233 | Occasional review: influenza in COPD: pathogenesis, prevention, and treatment |
| Q39651456 | Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection |
| Q30351736 | Oseltamivir in the management of influenza. |
| Q34759825 | Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer |
| Q30374740 | Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08 |
| Q36949482 | Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice |
| Q30452892 | Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors |
| Q34405859 | Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181 |
| Q30450742 | Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors |
| Q46417983 | Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses |
| Q33776525 | Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host |
| Q30387332 | Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts |
| Q22305941 | Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors |
| Q45036693 | Resistant influenza A viruses in children treated with oseltamivir: descriptive study |
| Q40193825 | Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice |
| Q57726187 | Sensitivity of H5N1 influenza viruses to oseltamivir: an update |
| Q30425350 | Surveillance for antiviral resistance |
| Q36870919 | Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. |
| Q33639979 | T-705 (favipiravir) activity against lethal H5N1 influenza A viruses |
| Q30410229 | The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses |
| Q30394937 | The validation of a real-time RT-PCR assay which detects influenza A and types simultaneously for influenza A H1N1 (2009) and oseltamivir-resistant (H275Y) influenza A H1N1 (2009) |
| Q30352557 | Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic. |
| Q28344588 | Treatment of influenza with neuraminidase inhibitors: virological implications |
| Q35124722 | Zanamivir in the treatment of influenza |
| Q40419399 | Zanamivir: an influenza virus neuraminidase inhibitor |
Search more.